Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Experimental Medicine Clinical Research Facility hosted by the Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences has expanded its capability to undertake research bronchoscopies. The facility welcomed its first volunteers as part of the Oxford Airways Study to help understand the causes of asthma.

On 11 June 2023 the emergency department at the John Radcliffe Hospital, Oxford experienced its busiest day. On top of the usual emergency patients, over 300 people turned up with severe breathing difficulties related to asthma. The cause was thought to be rye grass pollen, and a powerful summer thunderstorm.

During this unusual type of event, it's thought that a combination of high pollen levels, air pollution, strong winds and heavy rain during the warmer weather causes pollen to burst into tiny particles that are small enough to bypass the body's usual defence mechanisms and reach the lungs of asthma sufferers. This effect has been dubbed 'thunderstorm asthma'. With 1 in 12 people suffering from asthma, the storm had the potential to affect nearly 13,000 people in Oxford alone.

Professor Timothy Hinks, Wellcome Trust Fellow and Honorary Consultant at NDM’s Respiratory Medicine Unit, is carrying out research into the causes of asthma, which will help advise asthmatics on how to prepare and respond to such events. His research project, the Oxford Airways Study, which is supported by the NIHR Oxford Biomedical Research Centre, has been the first to carry out bronchoscopies in a new facility located at the Oxford Experimental Medicine Clinical Research Facility (Oxford EMCRF).

This capability was established by a £260K grant from the Medical Research Council, secured by Prof Hinks. It complements recent investment in gastrointestinal endoscopy equipment funded by NIHR and allows the EMCRF to expand the number and type of early-phase respiratory and gastroenterology trials at the University of Oxford. At least 13 groups plan to make use of the facility to study a range of diseases including asthma, interstitial lung diseases (lung fibrosis), infections (including COVID, pneumonia, and bronchiolitis), vaccines (including TB), gut immunology and inflammatory bowel disease.

Prof Hinks said: 'People are not born with asthma; it's brought on by a variety of factors. We are trying to understand why people get the condition by looking at the genes within the cells and to do this we need to take samples from the lung. The state-of-the-art equipment at the EMCRF comes with excellent optics and narrow bronchoscopes which make the procedure much more comfortable for research participants. Cells are swept from the lining of the lung and tiny biopsies are taken to be studied back in the lab. We hope that our work will not only help to develop new treatments but perhaps one day cure some forms of asthma.'

Alison Ambrose suffers from asthma, as does her husband and two of her children. She was referred to a specialist after seeing her condition deteriorate in the last few years and it's here that she became aware of the Oxford Airways Study and agreed to take part. 'I recently had blood tests, a chest X-ray and a CT scan done which had shown that past infections from TB in my twenties and pneumonia in my thirties as well as continuing inflammation had caused my asthma to fluctuate. I thought that joining a research project would help me understand more about my asthma. There are 550 people taking part in the research project but only a few are invited to have a bronchoscopy. The advantage of a bronchoscopy is that a doctor can see inside your lungs and take samples away for analysis so potentially this can help to find out more about the causes of infection. Despite the risks and my worry about having the procedure, I could see that this was a real opportunity for me and the research team to both build up a fuller picture of why I experience asthma and in turn how this research could be a positive way forward to help people manage their asthma and other airway diseases.'

The Oxford Airways Study is still recruiting patients with asthma as well as healthy people, and participants can find out more here

The Jenner Institute is also lined up to use the bronchoscopy facility for a study exploring an alternative method to deliver the TB vaccine, a serious illness affecting the lungs which is still prevalent in many parts of the world.

Similar stories

The potential of the R21/Matrix vaccine to redefine malaria prevention

Researchers from the Jenner Institute at NDM will present new exciting data on the R21/Matrix-M malaria vaccine during the 8th Pan-African Malaria Conference, in collaboration with the Rwandan Ministry of Health and the Rwanda Biomedical Centre.